FindTrial
Sign In

Laboratory Biomarker

OTHER3 trials

Sponsors

City of Hope Medical Center, Vanderbilt-Ingram Cancer Center

Conditions

Adenocarcinoma of the ProstateHER2 NegativeInvasive Breast CancerLung CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Breast CancerStage IV Prostate Cancer

Phase 1

Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
CompletedNCT02048150
City of Hope Medical CenterAdenocarcinoma of the Prostate, Stage IIB Prostate Cancer, Stage III Prostate Cancer +1
Start: 2015-03-05End: 2023-02-01Updated: 2023-03-21

Phase 2

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
CompletedNCT03206203
Vanderbilt-Ingram Cancer CenterHER2 Negative, Invasive Breast Cancer, Stage IV Breast Cancer +1
Start: 2017-08-29End: 2023-10-04Updated: 2024-12-12

Unknown Phase

Early Detection of Lung Cancer
Active, not recruitingNCT03181256
Vanderbilt-Ingram Cancer CenterLung Cancer
Start: 2017-12-14End: 2025-12-01Updated: 2025-10-01

Related Papers

Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
UNC Libraries2024-10-09
Abstract PS11-07: High prevalence of HER2-Low and AR expression in breast cancer brain metastases provide novel therapeutic options
Cancer Research2024-05-021 citations
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer
JAMA Oncology2023-12-1425 citations
1002 Intratumor heterogeneity in MHC-I expression drives immunotherapy resistance and exposes NKG2A as a therapeutic target in breast cancer
Regular and Young Investigator Award Abstracts2023-10-31
A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
Journal of Clinical Oncology2020-05-203 citations